Sandoz Group AG Overview
Pro stress-test →Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, with the firm maintaining a significant presence in Europe, the United States, and other key international markets, while generating remaining sales from biosimilars.
Strategic Profile
Pro stress-test →Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015, and currently has eight commercialized biosimilars in a number of markets with over 20 assets in its pipeline. Biosimilars now account for 31% of net sales, reflecting the company's strategic pivot.
Competitive Landscape
Pro stress-test →Sandoz competes in the highly fragmented generic and biosimilar pharma market with competitors including Teva, Dr. Reddy's, Hikma, and emerging biosimilar players. The company's competitive advantages lie in complex injectables, pioneering biosimilar experience, and global manufacturing scale. Price erosion remains a persistent industry challenge affecting all participants.
Industry Context
Sandoz Group AG operates in Drug Manufacturers - Specialty & Generic.
Key facts
Founded: 1886 · Headquarters: Basel, Switzerland · Employees: 20,000 · Revenue: $10.6B · Market cap: $32B